UNSPSC 41202069: Varicella-zoster virus serological reagents

In this classification, Varicella-zoster virus serological reagents are devices used in test to identify specific Varicella-zoster virus antibodies in serum. US FDA regulates Varicella-zoster virus serological reagents under 21 CFR 866.3900 and under FDA product code GQW.

UNSPSC 41202069 Varicella-zoster virus serological reagents is a Commodity code that encompasses rapid diagnostic test kits and reagent supplies for infectious disease screening, though state and local governments are currently sourcing these materials under this code primarily for HIV, syphilis, and hepatitis testing rather than varicella-zoster virus detection specifically. Recent solicitations show that state and local issuing bodies—including county criminal justice departments, municipal health agencies, state departments of public health, and higher-education institutions—are procuring serological test kits, reagent supplies, automated screening instrumentation, and related laboratory consumables to support disease surveillance, public health screening programs, and clinical diagnostics. Collin County Community Supervision and Corrections Department issued an RFP (2026-327, due July 23, 2026) for offender specimen collection and drug testing services valued at $600,000, though this opportunity encompasses immunoassay and confirmatory testing across multiple substance-testing modalities rather than viral serology alone. The City of Austin posted an IFB (9100AAM1023, due July 17, 2026) for rapid HIV Type 1 and Type 2 test kits to supply the Austin Public Health Program. The Illinois Department of Public Health Division of Laboratories issued an emergency procurement for Abbott HIV and Syphilis reagents and related supplies, along with a competitive IFB (26482DPHOFCDIB50489, due March 16, 2026) for a five-year contract covering fully automated combination screening instrumentation and assays for Hepatitis B, Hepatitis C, HIV-1/HIV-2, and Syphilis across Jackson County.

Activity is concentrated in Texas and Illinois, with Texas criminal justice and municipal public health agencies driving near-term demand and Illinois pursuing both emergency sole-source purchases from Abbott Laboratories and competitive bids for automated multi-analyte screening platforms. The University of Houston also posted an RFP (RFP-730-UofH-3109, due March 24, 2026) for clinical diagnostic laboratory services including blood chemistry reagents and nonautomated testing, though this opportunity sits at the margins of the code's scope. Recent opportunities span competitive sealed-bid and IFB processes with multi-year contract terms (two to five years base with renewal options), per-test or per-unit pricing models, and requirements for CLIA or equivalent laboratory certification, FDA approval, and automated instrumentation integration with existing laboratory information systems. No set-aside designations or disadvantaged-enterprise restrictions appear in the recent solicitations, though the Illinois opportunities include domestic-product preference and small-business program participation opportunities.